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http://dx.doi.org/10.1016/j.ccr.2014.04.015SUMMARYResidence of cancer-propagating cells (CPCs) within preferential microenvironmental niches has a major
part in evading therapy. However, the nature of niches involved and themechanisms protecting CPCs remain
largely unknown. We addressed these issues in mouse transplantation models of acute lymphoblastic leuke-
mia (ALL). When the engrafted leukemic cells substantially damaged adjacent microenvironment in the bone
marrow (BM), after chemotherapy small foci of CPCs were retained, surrounded by sheaths of supporting
cells that comprise a protective niche. We investigated patients’ BM biopsies and found evidence of a similar
process in patients receiving induction therapy. The efficacy of chemotherapy was enhanced by interfering
with the niche formation or function. We therefore identified a therapy-induced niche that protects CPCs.INTRODUCTION
Surviving cancer-propagating cells (CPCs) after therapy cause
relapses. Studies on this issue have focused on cell-intrinsic as-
pects, including the importance of differentiation stage or epige-
netic programs in resistant subpopulations, or the importance of
genetic variegation among different subclones in an individual
cancer (Anderson et al., 2011; Ding et al., 2012; Hong et al.,
2008; Kreso et al., 2013; Notta et al., 2011; Sharma et al.,
2010). However, evidence has suggested that subclonal resi-
dence of CPCs within preferential microenvironmental niches
may have a major part in evading therapy, but this issue should
be further investigated in terms of the nature of niches involved
and the mechanisms that protect surviving subclones (Lane
et al., 2009; Meads et al., 2009).Significance
Evasion of therapy by CPCs is one of the main obstacles in c
‘‘refuge’’ within preferential niches. We identified a protective
to therapy in the mousemodels of ALL. The niche was dynamic
their transition to a-SMA+ cells, and ending with fiber residue
patients who achieved only partial or nonremission after primar
significantly to the failure of achieving complete remission. The
formation of the early protective niche.
778 Cancer Cell 25, 778–793, June 16, 2014 ª2014 Elsevier Inc.Recent advances in the knowledge of normal hematopoietic
stem cell (HSC) niches and technologies applied to investigate
such niches have allowed us to investigate these issues in the
context of leukemia in the bone marrow (BM). HSCs are thought
to reside in at least two distinct niches (Wilson and Trumpp,
2006). An endosteal niche harbors quiescent HSCs and is
defined anatomically by its immediate proximity to the endos-
teum (an inner bone surface) (Calvi et al., 2003; Kiel et al.,
2005; Zhang et al., 2003). This niche is mainly composed of oste-
oblastic lining cells (expressing N-cadherin). By contrast, a
vascular niche provides a site for HSC proliferation and differen-
tiation (Kiel et al., 2005). This niche is located more centrally in
BM cavities and mainly contains sinusoidal endothelial cells.
The mechanism by which BM niches support HSCs can be
applied to protect leukemia-propagating cells (LPCs). Thisancer treatment. The surviving CPCs are presumed to find
niche within the BM that was created by CPCs in response
ally transient: beginning with Nestin+ cells, maturing through
s. We found the niche was recurrent in BM biopsies of ALL
y therapy, indicating that the niche formationmay contribute
refore, therapeutic strategies should seek to circumvent the
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Figure 1. Ex Vivo Imaging of Leukemic
Dissemination in Mouse BM
(A) Imaging of the residing and engrafting NALM-6-
GFP cells in the BM. D0, D1, D3, D5, D6, D7, D9, D11,
and D12 from day 0 to day 12 posttransplantation of
leukemic cells. Red dye DiI indicates the vascular
structure. Leukemic cells are green (GFP).
(B and C) Imaging of the residual cells in the mouse
BM after chemotherapy. B, bone; BM, bone marrow;
D6, D6 model; D12, D12 model; A0D, not treated with
Ara-C; A2D, treated with Ara-C for 2 days; A4D,
treated with Ara-C for 4 days. Scale bars represent
50 mm.
See also Figure S1 and Movie S1, S2, S3, S4, and S5.
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LPCs Rebuild an Evolving Niche to Evade Therapymechanism has been investigated using a xenograft leukemia
model. Leukemic cells reside and engraft in normal endosteal
niches that are quiescent and resistant to chemotherapy (Ishi-
kawa et al., 2007; Saito et al., 2010). However the scenario
seems complicated, because other studies have observed that
the growth of leukemic cells alters BM environments and inter-
feres with normal hematopoiesis (Colmone et al., 2008;
Schepers et al., 2013; Zhang et al., 2012). Therefore, the nature
of nonmalignant supporting cells that form a BM niche for
leukemic cells and the dynamic interplay between leukemic cellsCancer Cell 25, 778and niche components, particularly during
primary therapy, remains unclear.
We addressed these issues by investi-
gating in mouse transplantation models of
acute lymphoblastic leukemia (ALL). We
performed ex vivo imaging and immunoas-
says as well as investigated the patients’
BM biopsies. The results reveal the interplay
between LPCs and their nonmalignant sup-
porting cells in the BM and the initial events
resulting from primary chemotherapy.
RESULTS
Leukemic Dissemination Damages
BM Microenvironments
We transplanted human leukemic cells into
advanced immunodeficient animals to
observe their behaviors in BM niches.
Consistent with other studies (Notta et al.,
2011), the engraftment and extent of
leukemic dissemination were similar in
NOD. CB17-Prkdcscid /J (NOD/SCID) mice
treated with anti-CD122 that depletes innate
immune cells (NS122) or NOD/SCID mice
harboring the deletion of the common
gamma (g) chain (NOG) (Anderson et al.,
2011; Hong et al., 2008). Thus, the majority
of our study was conducted using the
NS122 model.
GFP-labeled NALM-6 cells, a human ALL
cell line, was injected into sublethally irradi-atedmice via the tail vein. Afterward, we performed ex vivo imag-
ing to observe the residence and dissemination of leukemic cells
in BM niches (Figure S1A available online) (Xie et al., 2009).
Vascular structures in the BM were visualized by red dye DiI.
Images were captured on days 0, 1, 3, 5, 6, 7, 9, 11, and 12 after
leukemic cells were injected. Sublethal irradiation damaged the
vascular structures, but these structures were rapidly restored
(days 0 to 3; Figure 1A) as previously reported (Hooper et al.,
2009). Imaging on day 1 showed that leukemic cells resided in
regions identified as endothelial microdomain juxtaposed to the–793, June 16, 2014 ª2014 Elsevier Inc. 779
Figure 2. A Protective Niche Is Induced by
Therapy within BM
(A and B) H&E staining of femur sections from the
mice of the D6 (A) and D12 (B) model.
(C and D) Immunohistochemical staining of femur
sections from the mice of the D6 (C) and D12 (D)
model. Brown dots are residual leukemic cells.
(E and F) H&E staining of femur sections from the
control (Ctr) mice that were not transplanted with
any human cells but received preirradiation (E) and
the mice that were transplanted with normal hu-
man cord blood (CB) progenitor cells and received
preirradiation (F). All mice treated with Ara-C for
2 days or 4 days. Scale bars represent 100 mm.
See also Figure S2.
Cancer Cell
LPCs Rebuild an Evolving Niche to Evade Therapyendosteum (Colmone et al., 2008; Sipkins et al., 2005).
Serial images from days 3, 5, 6, 7, 9, 11, and 12 showed
that leukemic cells engrafted and grew in themicrodomain, grad-
ually spread out to adjacent regions, and eventually invaded the
whole marrow cavity (Figure 1A). With such leukemic dissemina-
tion, the vascular structure remained intact until day 6 but
was gradually ruined from day 7 and completely became780 Cancer Cell 25, 778–793, June 16, 2014 ª2014 Elsevier Inc.unvisualizable on day 12 (Figure 1A;
Movies S1, S2, S3, S4, and S5).
We subsequently examined N-cad-
herin-expressing osteolblastic-lining cells
to determine whether or not the leukemic
dissemination also affects endosteal
niches. In line with the alteration of
vascular structures, the endosteal linings
showed significant damage on day 7
and became unvisualizable on day 12
(Figure S1B). Thus, leukemic dissemina-
tion in BM dynamically and synchro-
nously damaged normal endosteal and
vascular microenvironments.
A Protective Niche Is Induced by
Chemotherapy within BM
We investigated the relationship be-
tween leukemic cells and niches during
administration of the chemotherapeutic
agents, cytarabine (Ara-C) and/or
daunorubicin (DNR), those are the first-
line drugs for ALL patients (Mi et al.,
2012). This experiment was performed
in an undisrupted or ‘‘normal’’ niche pre-
sent at D6 of leukemic establishment (D6
model) and in a leukemia-decimated
niche at D12 (D12 model) (Figure 1A).
In both settings, Ara-C treatment for 2
(A2D) and 4 days (A4D) was used to
reduce the leukemic cell burden in refer-
ence to the related literature (Boyerinas
et al., 2013; Ishikawa et al., 2007; Saito
et al., 2010), and our pilot experiments
showed that mice could endure maximal
4 day treatment of this agent.A small number of leukemic cells residing in the BM were
observed by ex vivo imaging in mice of both D6 model and
D12 model (Figures 1B and 1C). We subsequently sectioned
the BM tissues and conducted hematoxylin and eosin (H&E)
staining (Figures 2A and 2B) and anti-GFP immunostaining
(Figures 2C and 2D) to define the specific location of residual
leukemic cells and their association with BM niches. In mice
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LPCs Rebuild an Evolving Niche to Evade Therapyrepresenting the D6 model, the residual leukemic cells were
located in normal niches of endosteal and vascular types (Fig-
ures 2A and 2C). By contrast, the residual cells were located in
a previously unidentified niche in mice from the D12 model.
Morphologically, the niche is composed of homogeneous
mesenchymal cells (Figures 2B and 2D). Hereafter, we focused
on the identification of the niche, and the mice analyzed were
all from the D12 model given no particular indication.
Similar niches were produced in models of other ALL cell lines,
REH, and Sup-B15 by administering Ara-C or DNR (Figure S2A),
indicating that the niche formation may be a common event that
occurs in ALL.
The niches were not induced in the control animals that
received same irradiation but not leukemia transplantation, indi-
cating irradiation did not contribute to the niche formation (Fig-
ure 2E). Actually, the typical niche was also observed in the
leukemic mice that were not receiving preirradiation, which
further supported that the niche was not resulted from irradiation
(Figure S2B).
The control of normal HSC (isolated from human cord blood)
transplantation was used. The niche was not induced in the
recipient mice despite high engraftment up to 90% obtained,
indicating the niche may be only associated with malignant he-
matopoietic cells (Figure 2F).
To determine the natural history of the development of the
niche over longer periods, we induced the niche by A2D in a
group of leukemic mice simultaneously in the same condition
and sacrificed three mice every day from days 0 to 11 (+0d
to +11d) posttreatment to monitor the changes of the niche by
H&E staining of BM sections. After the therapy was terminated,
the niche appeared until +7d (images at +0d, +1d, and +3d
were shown) and was disappearing from +8d to +11d with only
residues of cell-extracellular matrix and fibers remained, respec-
tively (Figure S2C). The fibers were Gomori (GO) stain positive
indicating reticulin fibers (Figure S2D). Therefore, the therapy-
induced niche was dynamically transient.
The tissues of liver, lung, spleen, brain, heart, and kidney of the
mice were also analyzed for presence of residual disease after
A2D and A4D. Moderate leukemic dissemination was detected
in liver, lung, and spleen, and not in brain, heart, and kidney of
A0D mice. After A2D or A4D, only a minimal number of leukemic
cells resided in spleen and not in lung and liver (Figure S2E). The
results are consistent with the view that BM microenvironment
may provide a primary site for minimal residual disease in leuke-
mia (Garson et al., 1989; Preisler et al., 1989).
The Therapy-Induced Niche Is Composed by
Phenotypically Dynamic Mesenchymal Cells
Mesenchymal markers including Nestin, alpha-smooth muscle
actin (a-SMA), Vementin, Desmin, fibroblast activation protein
(FAP), and fibroblast-specific protein 1 (FSP1), endothelial
markers including CD31, VE-cadherin (CD144), and hematopoi-
etic markers including CD45, and Ter119 were immunoassayed
to identify the cells that compose the therapy-induced niche. The
niche cells at the early stage (A2D) were, among the mesen-
chymal markers tested (Figures 3A, 3B, and S3A), Nestin-posi-
tive (Nestin+, Figure 3A), and coexpressed Vimentin mostly
(Figure 3B) and a-SMA partially (Figure S3A), indicating they
were mesenchymal cells. Nestin+ cells were rarely observedbefore therapy (A0D; Figure 3A, left panel). The Nestin+ niche
cells at A2D were CD45-negative (CD45) and Ter119, indi-
cating they were not hematopoietic cells (Figure S3B). These
cells were CD31 and CD144, indicating they were not endo-
thelial cells (Figure S3C).
The niche cells at the later stage (A4D) were, among the
mesenchymal markers tested (Figures 3C, 3D, and S3D),
a-SMA+ (Figure 3C) and coexpressed Vimentin mostly (Fig-
ure 3D) and Nestin partially in the mesenchymal markers tested
(Figure S3D), indicating they were mesenchymal cells and might
develop from the niche cells at A2D. a-SMA+ cells were rarely
observed before therapy (A0D; Figure 3C, left panel). The
a-SMA+ cells at A4D did not express Mac-1 (Figure S3E), indi-
cating they were not macrophages as reported recently (Ludin
et al., 2012).
The Nestin+ cells at A2D were speculated to be mesenchymal
stem cells (MSCs) that have the capacity to form mesenspheres
and the developmental potential of multiple mesenchymal line-
ages in conditional cultures (Me´ndez-Ferrer et al., 2010). To
test this proposition, BM cells were harvested and the Nestin+
cells were immunophenotypically analyzed and flow-sorted for
functional assays because they expressed chemokine (C-C
motif) receptor 1 (CCR1) (Figures 3E and 3F). First, these cells
uniformly expressed CD51 and CD29 (85.2% ± 2.9% and
83.5% ± 3.9%, respectively) ( Figures 3G, 3H, and S3F), which
have been reported expressed by Nestin+ MSCs in normal
BM (Pinho et al., 2013). Second, these cells had ability to form
replatable mesenspheres in the conditional medium (Figure 3I)
(Me´ndez-Ferrer et al., 2010). Third, the cells became oil red
stain-positive in adipogenic differentiation medium and alizarin
red stain-positive in osteogenic differentiation medium, indi-
cating that such cells were differentiated to adipocytes and
osteoblasts, respectively (Figure 3J). Together, the results prove
that the Nestin+ niche cells in the A2D mice are MSCs.
Leukemic Cells Secrete Cytokines to Recruit
Mesenchymal Cells and Build the Therapy-Induced
Niche
Given distinct Nestin+ cells in BM segregate with distinct vessels
and function differently in supporting normal hematopoiesis by
forming different prevascular niches (Kunisaki et al., 2013), we
further immunophenotypically characterized the Nestin+ niche
cells in the A2D mice. Immunoassay of isolated cells (Figure 4A)
and of BM tissues in situ (Figure S4A) showed that these cells
were LepR+ and NG2, which was also confirmed by flow cyto-
metric analysis (Figure 4B). Phenotype LepR+ NG2 indicates
that the Nestin+ cells in A2D mice might be recruited from BM si-
nusoidal niches rather thanarteriolar niches (Kunisaki et al., 2013).
Then what factors recruit these cells to form the niche?
Considering that the niche was not induced in the mice without
transplanted leukemic cells (Figure 2E), we proposed that
leukemic cells may have an important function in the niche for-
mation. To verify this assumption, we examined the differential
gene expression between leukemic cells in A2D mice and those
in A0D mice by microarray-based profiling. This analysis re-
vealed that the gene expression of some cytokines, including
chemotactic factors, e.g., chemokine (C-C motif) ligand 3
(CCL3) and growth factors, e.g., transforming growth factor-
beta1 (TGF-b1) and growth differentiation factor 15 (GDF15),Cancer Cell 25, 778–793, June 16, 2014 ª2014 Elsevier Inc. 781
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Figure 3. The Therapy-Induced Niche Is Composed by Phenotypically Dynamic Mesenchymal Cells
(A andB) Immunoassay of Nestin (A andB), GFP (A), and Vimentin (B) on the BMof A2D and/or A0Dmice. Scale bars represent 100 mm (A, left andmiddle panel) or
20 mm (A, right panel, and B).
(C and D) Immunoassay of a-SMA (C and D), GFP (C), and Vimentin (D) on the BM of A4D and/or A0Dmice. Scale bars represent 100 mm (C, left andmiddle panel)
or 20 mm (C, right panel, and D).
(E) Immunoassay of Nestin and CCR1 on the niche cells isolated from the BM of A2D mice. Scale bar represents 100 mm.
(F) Flow cytometric analysis of CCR1 expression on the niche cells isolated from the BM of A2D mice.
(G and H) Flow cytometric analysis of CD51, CD29 (G) and indicated cell surface makers (H) in the CCR1+ niche cells isolated from the BM of A2D mice.
(I) Mesensphere-forming assay of the flow-sorted niche cells from A2D mice. Scale bar represents 500 mm.
(J) In vitro developmental assay of the flow-sorted niche cells from A2D mice in adipogenic or osteogenic differentiation medium. Scale bar represents 200 mm.
All data are mean ± SD of triplicates in an independent experiment, which were repeated at least for three times the same results.
See also Figure S3.
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LPCs Rebuild an Evolving Niche to Evade Therapywas upregulated (Figure 4C), indicating that leukemic cells may
secrete these factors into the BM environment in response to
therapy. The array data were validated by real-time PCR
(Figure 4D).782 Cancer Cell 25, 778–793, June 16, 2014 ª2014 Elsevier Inc.We investigated the functional roles of these cytokines in the
niche formation. After the expression of the receptor of CCL3
(CCR1) was determined in the niche cells isolated from the
A2D mice (Figures 3E and 3F), the chemoattractant effect of
Cancer Cell
LPCs Rebuild an Evolving Niche to Evade TherapyCCL3 on the niche cells was assayed in a trans-well cultured sys-
tem. CCL3 was observed to significantly accelerate the migra-
tion (Figures 4E and 4F). In addition, CCL3, which is also a
growth factor, was observed to expand the niche cells in the me-
dium optimized for MSCs (MSCmedium) (Figure 4G). Consistent
with this result, the dividing Nestin+ cells were easily observed in
the BM of the A2D mice (Figure 4H). Neutralizing anti-CCL3 anti-
body and CCR1 inhibitor BX471 were respectively used immedi-
ately after the chemotherapy agent was administrated to further
verify the role of CCL3 in the niche formation in vivo. Interfering
with CCL3 significantly reduced the Nestin+ cells in forming the
niche at A2D (Figures 4I and S4B) and did not affect their transi-
tion to a-SMA+ (Figures 4J andS4C) and consequently facilitated
the removal of leukemic cells by cytotoxic agents (Figures S4D
and S4E). These results suggest that Nestin+ cells were recruited
and expanded by the leukemic cell-secreted cytokine to initiate
the therapy-induced niche.
The results of immunoassay implied that a-SMA+ cells at A4D
develop from Nestin+ cells at A2D (Figures 3 and S3). To verify
this transition, the flow-sorted Nestin+ cells were maintained in
the MSC medium (Figure 4K, upper panels), and the recombi-
nant TGF-b1 was added because it was reported to have
the ability to induce MSCs to a-SMA+ cells (Wang et al., 2004)
and upregulated in the residual leukemic cells (Figures 4C and
4D). Seven days after addition of TGF-b1, the cells became
a-SMA+ (Figure 4K, lower panels), which demonstrated the
transition of the niche cells from Nestin+ to a-SMA+. Further,
normal BM and leukemic BM of the A2D mice (containing
leukemic cells) was added to the MSC medium culture, respec-
tively, to determine whether leukemic cells mediated the transi-
tion. Indeed, the Nestin+ to a-SMA+ transition was observed
in the culture with leukemic BM but not in that with normal BM
(Figure S4F).
Neutralizing anti-TGF-b1 antibody and the receptor (TGF-bRI/
II) inhibitor Ly2109761 were respectively used immediately after
the chemotherapy agent was administrated to further verify the
role of TGF-b1 in the niche formation in vivo. Interfering with
TGF-b1 did not affect Nestin+ cells in the niche initiation at A2D
(Figures 4L and S4G), rather inhibit transition to a-SMA+ (Figures
4M and S4H). The therapy efficacy was not affected (Figures S4I
and S4J). Together the leukemic cell-secreted TGF-b1 induced
the niche cell transition from Nestin+ to a-SMA+.
Altogether, the residual leukemic cells have a major function in
the therapy-induced niche formation by secreting cytokines to
recruit and modify the niche cells. The niche begins with Nestin+
MSCs and matures via transition of Nestin+ to a-SMA+ cells.
Hereafter, the niche is termed NSM niche. Amodel of NSM niche
formation is shown in Figure 4N.
NSM Niche Does Not Provide Physical Protection to
Resident Cells
We initially determined whether or not NSM niche produces a
physical barrier for drug delivery to find a possible protective
mechanism of NSM niche to leukemic cells. We administered
DNR by intravenous injection into A2D and A4D mice, respec-
tively. After 5 min, the cranium was removed for ex vivo imag-
ing. The images showed that the drug could be effectively
delivered to the vicinity of the residual cells in A2D mice (Fig-
ures S5A and S5B) and A4D mice (Figures S5C and S5D), indi-cating that NSM niche did not provide physical protection from
drug delivery.
We analyzed the cell-cycle status of the residual cells by
immunoassay of Ki-67 expression. In the NALM-6 cell model,
most residual cells (GFP+) expressed Ki-67 (Figures S5E and
S5F). In the primary leukemic cell model, the residual cells
were both in the cycling and quiescent phases (Figures S5G
and S5H), indicating that NSM niche did not exclusively protect
leukemic cells by maintaining them in the quiescent phase.
GDF15 Has an Essential Function in NSM Niche
Protection
We then investigated whether or not NSM niche endowed its
resident leukemic cells with drug resistance. The leukemic cells
in the A2D mice were isolated and cultured in an apoptosis
analysis system. The results showed that the cells were indeed
more resistant to Ara-C-induced apoptosis in comparison with
the leukemic cells isolated from A0D mice (Figures 5A and 5B).
To reveal how the niche-resident cells were drug-resistance-
transformed, we came back to the results of differential gene
expression analysis. Among the significantly changed genes,
GDF15 was interesting because its expression was remarkably
upregulated (z32-fold) in the residual leukemic cells (Figures
4C and 4D) and it was reported to confer drug resistance on
other cancer cells (Bauskin et al., 2005; Corre et al., 2012). The
protein level in the cell lysate and ex vivo culture supernatant
of the leukemic cells isolated from A0D and A2D mice was de-
tected by western blot (WB). While it was not changed in the
cell lysate, GDF15 in the supernatant was significantly higher in
the culture of leukemic cells from A2D mice than that from A0D
mice, confirming that residual leukemic cells in the A2D mice
secreted GDF15 into the niche (Figure 5C). The secreted
GDF15was a 72 kDa propeptide (pro-GDF15, Figure 5C). Never-
theless, pro-GDF15 needs to be cleaved by proconvertases,
thereby releasing a 24 kDa mature protein (mGDF15) that con-
fers drug resistance on cancer cells (Bauskin et al., 2005; Corre
et al., 2012).
We applied the recombinant humanmGDF15 (rhGDF15) in the
apoptosis analysis culture of NAML-6 cells to determine whether
or not the drug resistance transformation was directly mediated
by mGDF15. Results showed that leukemic cells appeared
significantly more resistant to Ara-C-induced apoptosis at the
presence of rhGDF15 (Figure 5D).
We then used a retrovirus-delivered interference RNA target-
ing GDF15 (iGDF15) and nonsilencing control (NSC) to determine
whether or not interference with GDF15 function can improve
the chemotherapy outcome in the leukemic mice (Figure 5E).
GDF15 knockdown in NALM-6 cells (iGDF15) was validated by
WB analysis in comparison with NSC and mock control (Fig-
ure 5F). GDF15 knockdown in NALM-6 cells did not affect their
sensitivity to cytotoxic agents in vitro (Figure S5I). Their engraft-
ment in NS122 mice was also not affected as observed by
ex vivo imaging (Figure 5G). The use of A2D or A4D in these
leukemic mice yielded a significantly different outcome. Fewer
residual cells were observed in iGDF15 mice compared with
those in NSC and mock control mice (Figures 5H and 5I). We
calculated the absolute numbers of the residual cells in the fields
of Figures 5H and 5I on right panels. The average number of a
4.5 3 103 mm2 field in iGDF15 mice was significantly reducedCancer Cell 25, 778–793, June 16, 2014 ª2014 Elsevier Inc. 783
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LPCs Rebuild an Evolving Niche to Evade Therapy(Figure 5J). BM H&E staining showed that the NSM niche did not
exhibit morphological differences among mock, NSC, and
iGDF15 mice (Figure 5K). Furthermore, mouse survival experi-
ments showed that the survival benefit of interfering with
GDF15 was indeed endowed to the leukemic mice after A2D,
although this might be compromised by other factors such as
innate weakness of immunodeficient mice (Figure 5L).
Consistent with these findings in iGDF15 mice, intraperitoneal
application of neutralizing anti-GDF15 antibody (1 mg/mouse)
at 4 hr after Ara-C was injected significantly reduced the residual
leukemic cells (Figures S5J and S5K) and did not limit the forma-
tion of the NSM niche (Figure S5L).
Together, intervention in the expression or function of GDF15
facilitated the removal of NSM niche-resident leukemic cells by
cytotoxic agents and thus demonstrated GDF15 has an essential
function in NSM niche protection.
NSM Niche Cells Provide Furin to Process GDF15
The niche cells in the A2D mice was harvested and added into
the ex vivo culture of the residual leukemic cells isolated from
A2D mice to determine whether or not the niche cells play
roles on the process of GDF15. Before addition of the niche
cells, all GDF15 was pro-GDF15 (72 kDa) (Figure 5C, middle
panel), whereas after the niche cells were added to the culture
pro-GDF15 became mGDF15 (24 kDa) in 24 hr (Figure 6A,
upper panel). Among the proconvertase tested by RT-PCR,
Furin was found expressed in the isolated niche cells (Fig-
ure 6B). In line with this, when the Furin inhibitor, chloromethyl-
ketone (CMK) was added into above ex vivo culture the transi-
tion of pro-GDF15 to mGDF15 was inhibited ((Figure 6A, lower
panel).
CMK and control dimethyl sulfoxide (DMSO) was then phar-
macologically administrated in the A2D mice to further confirm
the essential role of Furin in processing GDF15 and thus mediate
the niche protection. Live imaging of the cranium showed that
administration of CMK significantly enhanced the elimination
of the leukemic cells by Ara-C (Figures 6C and 6D). The BM in
the femurs of the mice was flushed down, and the fluid was
harvested for WB analysis of GDF15. The results showed that
the process of pro-GDF15 to mGDF15 was markedly inhibited
by CMK in comparison with DMSO control (Figure 6E).Figure 4. Leukemic Cell-Secreted Cytokines Recruit and Modify Mese
(A and B) Immunoassay (A) and flow cytometric analysis (B) of Nestin (A) or CCR1
bars represent 100 mm.
(C and D) Microarray analysis (C) and real-time PCR validation (D) of cytokine
compared with that in engrafted cells of A0D mice.
(E and F) Photomicrograph (E) and quantification (F) of the migrated niche ce
chemoattractant in a transwell culture system. *p < 0.01, n = 3. Scale bar repres
(G) Proliferation of the niche cells cultured inMSC-medium in the absence or prese
assay. *p < 0.05, n = 3.
(H) Dividing Nestin+ cell in the BM of A2D mice as indicated by the arrow. Scale
(I and J) H&E staining (I) and immunoassay (J) of BM sections from the mice trea
represent 100 mm (I) or 20 mm (J).
(K) In vitro functional assay of development of CCR1+ niche cells isolated from the
for another 7 days. Scale bars represent 200 mm ((left panel) or 50 mm (right pan
(L and M) H&E staining (L) and immunoassay (M) of BM sections from the mice tre
represent 100 mm (L) or 20 mm (M).
(N) A model of the NSM niche formation. SV, sinusoidal vessel; BM, bone marrow
independent experiment, which were repeated at least for three times the same
See also Figure S4.To further visualize the process of GDF15 in the NSM niche
in situ, we immunoassayed the distribution of pro-GDF15 in
the NSM niche by using a human pro-GDF15-specific antibody.
Pro-GDF15 was not detected in the control mice without trans-
planted leukemic cells (Figure 6F). In the A0D mice, pro-GDF15
was restricted in leukemic cells (Figure 6G). In the A2D mice,
pro-GDF15 was distributed in residual cells as well as in NSM
niche possibly on the surface of the niche cells (Figure 6H). After
Furin was confirmed as present on the niche cell (Nestin+) (Fig-
ure 6I), pro-GDF15 was detected to be colocalized with Furin
on the niche cells, where pro-GDF15might be cleaved to release
mGDF15 (Figure 6J). Taken together, the results demonstrate
that the NSM niche cells process GDF15 by providing procon-
vertase Furin.
We then investigated whether or not mGDF15 triggers any
signaling pathway that may endow chemoresistance to leukemic
cells. From the microarray data, Smad3, one of the central ‘‘con-
duits’’ of the TGF-b signaling pathway, was upregulated at the
mRNA level in the leukemic cells of the A2D mice (Figure 6K).
Immunoassay using the antibodies specific for phosphorylated
Smad3 (p-Smad3) and nonphosphorylated Smad3, respectively,
showed that the protein was totally phosphorylated (Figure 6L).
By contrast, Smad3 and p-Smad3 were not detected when
GDF15 expressionwas interferedwith (Figure 5HandFigure 6M).
These data suggested that the Smad3-mediated TGF-b sig-
naling pathway was specifically activated by GDF15. The immu-
noassay indicated that mGDF15 was colocalized with TGF-b
receptor II (TGFbRII) on the surface of leukemic cells, which
further supported that mGDF15 activated TGF-b signaling
pathway (Figure 6N).
Therefore, our data revealed that a protective model is in the
BM where the NSM niche provides a foundation for its resi-
dent leukemic cells to secrete and process the stress-protein
GDF15, which in turn confers chemoresistance on the
leukemic cells by activating the TGF-b signaling pathway
(Figure 6O).
NSM Niche Protects Primary LPCs
Similar experiments were conducted with cells isolated from
BM aspirates of seven ALL patients (Table S1) to extend
our investigation with leukemic cell lines to primary patientnchymal Cells to Build the Therapy-Induced Niche
(B) and LepR or NG2 (A and B) in the niche cells isolated from A2D mice. Scale
genes upregulated more than 2-fold in the niche-resident cells of A2D mice
lls in the absence or presence of recombinant human CCL3 (rhCCL3) as a
ents 200 mm.
nce of rhCCL3 (100 ng/ml) was determined using the cell counting kit-8 (CCK-8)
bars represent 50 mm or 20 mm in inset.
ted with anti-CCL3 or control IgG antibody (Ab). *p < 0.01, n = 15. Scale bars
A2Dmice in MSC-medium for 2 days and in the presence of TGF-b1 (10 ng/ml)
el).
ated with anti-TGF-b1 or control IgG Ab. *p < 0.01, #p > 0.05, n = 15. Scale bars
; LPCs, leukemia-propagating cells. All data are mean ± SD of triplicates in an
results.
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Figure 5. Leukemic Cell-Secreted GDF15 Plays an Essential Role in NSM Niche Protection
(A and B) Apoptotic analysis (A) and viable cell quantification (B) of the leukemic cells isolated from the A0D and A2D mice. *p < 0.01, n = 3.
(C) Western blot (WB) analysis of GDF15 protein in the cell lysate (upper panel) and the ex vivo culture supernatant (middle panel) of the leukemic cells isolated
from the A0D or A2D mice.
(legend continued on next page)
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LPCs Rebuild an Evolving Niche to Evade Therapysamples. The seven samples sufficiently engrafted in NS122
mice were confirmed by detecting human immunophenotypes
(Figures 7A and 7B) (Anderson et al., 2011; Hong et al.,
2008). Five of the seven samples (samples 1–5) developed
leukemia (‘‘onset’’) in 15 weeks posttransplantation. The
mice transplanted with the other two samples (samples 6
and 7) appeared ‘‘healthy’’ in 15 weeks posttransplantation,
and this finding is consistent with a relatively low level of
engraftment present in these animals (Figure 7C and
Table S2).
The mice xenografted with the seven samples were then
treated with A2D or A4D. The therapy markedly reduced
leukemic cell burden (*p < 0.01; Figures 7D–7G; Table S2).
NSM niches were observed in all ‘‘onset’’ (Figure 7D) but not in
any ‘‘healthy’’ mice (Figure 7F). This result is consistent with
that of the cell line models, in which NSM niche formation is
dependent on the extent of leukemic dissemination.
The niche-resident cells were isolated from the primary A4D
mice of the three samples (samples 1–3), and serial transplanta-
tion was performed to determine whether or not these cells can
propagate leukemia. The leukemial propagation could be de-
tected in secondary and tertiary recipients, demonstrating that
the NSM niche-resident cells were LPCs (Figures 7H and 7I;
Table S2). Furthermore, limiting dilution assay in vivo in the
secondary recipient showed that LPC frequency within the resid-
ual leukemic cells isolated from the primary A4D mice
was significantly increased in comparison with the leukemic cells
isolated from the primary A0D mice (*p < 0.01; Figure 7J;
Table S2).
The robust development of NSM niche (5/7) in the xenograft
models of primary leukemic cells suggested that its formation
may be a recurrent pathogenic mechanism in ALL.
NSM Niche Is Induced in Murine Syngeneic Leukemia
Models
Given the physiological relevance of studies in xenograft models
of human leukemia was concerned (Kelly et al., 2007), we per-
formed the same experiments in three syngeneic models of
murine leukemia: oncogene N-Myc overexpression-induced
primary cell leukemia in C57BL/6 mice (Sugihara et al., 2012),
murine leukemia cell line L1210 in DBA/2 mice and TIB205 in
BALB/C mice, respectively (Figures S6A and S6B). In support
of our findings, NSMnicheswere observed in these threemodels
with typical morphology in H&E staining assay (Figures S6C–
S6E, upper panels) and typical phenotypes in immunoassays
(Figures S6F–S6H). The niche was not seen in any control (Ctr)
mice that received the same irradiation but no leukemic cell
transplantation (Figures S6C–S6E, lower panels). These similar
results in syngeneic models thus support that our findings in(D) Apoptotic analysis of the direct response of leukemic cells (NALM-6) to Ara-C
*p < 0.01, n = 3.
(E) The short-hairpin oligos of iGDF15 and NSC were cloned in a retroviral vecto
(F) WB analysis of GDF15 expression in NALM-6 cells after retroviral infection.
(G–J) Ex vivo imaging (G–I) and quantification (J) of GFP-labeled NALM-6-iGDF1
0.05, *p < 0.001, n = 3–7. Scale bars represent 500 mm or 100 mm in inset. All da
(K) H&E staining analysis of BM sections from the A2D and A4Dmice correspondi
the A2D mice.
See also Figure S5.xenograft models that may have implications in pathophysiology
of leukemia.
NSM Niche Is Recurrently Presented in ALL Patients
Achieving Only Partial or Nonremission after Therapy
In order to further confirm the pathophysiological relevance of
our findings, we obtained data from the Shanghai Jiao Tong
University-affiliated hospitals to determine whether or not NSM
niches are formed in the BM of patients. We also used these
data to investigate whether or not NSM niches are associated
with the outcome of chemotherapy because the hematology
departments obtain BM biopsies along with BM aspirates from
leukemia patients to assess the outcome of chemotherapy.
We comparatively analyzed 50 ALL patients whose biopsy sam-
ples were available after induction therapy (IT) and qualified for
the study. The following results were obtained: 30 patients
achieved complete remission (CR), 15 partial remission (PR),
and 5 nonremission (NR). Patients’ information is provided in
the Supplemental Experimental Procedures and Table S3.
Among the 20 PR/NR samples, 15 presented a morphologi-
cally typical NSMniche: residual leukemic cells were surrounded
by mesenchymal cells (Figure 8A). Immunoassays on the serial
sections of the same sample of Figure 8A showed that these
leukemic cells were enriched in the immunophenotype of
primary hematopoietic cells CD34+CD38 (Figures 8B and 8C).
Immunoassays also showed that these mesenchymal cells
were a-SMA+ (Figure 8D), Nestin (Figure 8E), and CD146 (Fig-
ure 8F), indicating that theNSMnichewas at the stage ofmaturity
when the biopsy was obtained. In addition, GO staining showed
that these samples were rich in reticulin fibers (Figure 8G). In the
remaining 5 of the 20 PR/NR samples, the fibers were still abun-
dant (Figure S7A) although no typical NSM niche was observed
(Figure S7B), indicating that the NSM niche was formed and
was in the final stage with the residual fibers remaining when
the biopsywas obtained, consistantwith the finding in themodel.
By contrast, the NSM niche was not observed in any CR sam-
ples (Figure 8A), and fibers were rarely found in these samples
(Figure 8G), indicating that the NSM niche was not induced in
CR patients.
Given that different fiber contents were observed between PR
and CR samples, we quantified the reticulin fiber density (RFD)
in these samples (Figure S7C; Table S3). RFD was significantly
higher in the PR/NR samples than that in the CR samples (*p <
0.01; Figure 8H), indicating that RFD is somewhat correlated
with the chemotherapy outcome, and this finding is consistent
with other clinical investigations (Nore´n-Nystro¨m et al., 2005,
2008).
Immunoassay of GDF15 and BCL-2, an antiapoptotic pro-
tein, was performed to determine whether or not NSM nichein vitro in the absence or presence of recombinant human mGDF15 (rhGDF15).
r driven by H1 promoter in the 30 long terminal repeat (LTR).
5, -NSC, and -mock cells in the BM of A0D (G), A2D (H), and A4D (I) mice. #p >
ta are presented as mean ± SD.
ng to that in (H) and (I). Scale bars represent 100 mm. (L) Survival experiments of
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Figure 6. NSM Niche Cell-Provided Furin Processes GDF15 to Activate TGF-b Signal Pathway
(A) WB analysis of GDF15 protein in the supernatants of the ex vivo cultures of the leukemic cells isolated from the A0D and A2Dmice, in the presence of the niche
cells of A2D mice without (upper panel) or with the inhibitor of Furin (chloromethylketone [CMK]) (lower panel).
(B) RT-PCR analysis of the proconvertases labeled in the niche cells isolated from A2D mice. PC, positive control; NC, no-template negative control.
(C and D) Ex vivo imaging (C) and quantification (D) of the residual leukemic cells in the A2Dmice in administration of CMK or control DMSO. *p < 0.01, n = 5. Scale
bars represent 500 mm or 100 mm in inset.
(E) WB analysis of GDF15 protein in the BM fluids harvested from the femurs of the corresponding mice of (C).
(F–J) Immunoassay of GFP (F–I), pro-GDF15 (F–H and J), Nestin (H and I) and Furin (I and J) in the BM of control (F), A0D (G), and A2D (H–J) mice. The arrows in (H)
indicate pro-GDF15 in the GFP+ leukemic cells (open arrows) and on the Nestin+ niche cell (solid arrow). Scale bars represent 50 mm or 10 mm in inset.
(K) Smad3 expression in the leukemic cells isolated from the A0D and A2D mice. p <0.01, n = 3.
(L and M) Immunoassay of GFP and either Smad3 or phosphorylated Smad3 (p-Smad3) in the BM of A2D mice (L) and A2D-iGDF15 mice (M) corresponding to
that in Figure 5H. Scale bar represents 20 mm.
(N) Immunoassay of the colocalization of mGDF15 and TGFbRII on the surface of the leukemic cells isolated from the A2D mice. Scale bar represents 20 mm.
(O) Working model of the therapy-induced NSM niche in protecting LPCs within BM. All data are mean ± SD of triplicates in an independent experiment, which
were repeated at least for three times the same results.
Cancer Cell
LPCs Rebuild an Evolving Niche to Evade Therapyin the patient BM supports the resident leukemic cells in the
similar mechanism as revealed in our models. The results
showed that GDF15 was distributed in NSM niche (Figure 8I)
and the niche-resident leukemic cells highly expressed BCL-2
(Figure 8J), indicating that GDF15 might provide residual788 Cancer Cell 25, 778–793, June 16, 2014 ª2014 Elsevier Inc.leukemic cells with chemoresistance in NSM niche as observed
in our models.
Together, these data suggested that NSM niche formation
was associated withmore difficulties to achieve complete remis-
sion after chemotherapy in ALL patients.
Figure 7. NSM Niche Is Induced in the Model of Primary ALL Cells
(A and B) Flow cytometric analysis (A) and H&E staining (B, left panel) and immunoassay (B, right panel) of human ALL cells in themouse BM. Scale bars represent
100 mm (B, left panel) or 50 mm (B, right panel).
(C) Summary of the leukemic engraftment of seven ALL patient samples in the mouse BM. ‘‘onset’’ mice, clinically manifested leukemia; ‘‘healthy’’ mice, low
engraftment.
(legend continued on next page)
Cancer Cell
LPCs Rebuild an Evolving Niche to Evade Therapy
Cancer Cell 25, 778–793, June 16, 2014 ª2014 Elsevier Inc. 789
Cancer Cell
LPCs Rebuild an Evolving Niche to Evade TherapyDISCUSSION
Increasing evidence suggests that the residence of CPCs in
preferential niches may have a major part in evading therapy
and in subsequent evolution. The nature of the niches involved
and the mechanisms by which the niche protects CPCs have
been investigated in this study in the context of human ALL by
investigating the mouse models and patients’ BM biopsies.
LPCs rebuild a protective niche to survive primary chemotherapy
when normal BM niches are substantially damaged by leukemic
dissemination.
We show that leukemic dissemination in the BM dynamically
altered normal microenvironments. The extent of the damage
depended on the level of leukemic cell engraftment and was
easily distinguished. Thus, we could consistently use the same
leukemic models to identify the nonmalignant supporting cells
of LPCs under distinct conditions. Prior to frank leukemic
dissemination, residual leukemic cells were located in normal
endosteal and vascular niches after initial chemotherapy. How-
ever, LPCs resided in a therapy-induced niche once leukemic
dissemination substantially devastated the normal BM environ-
ment. The niche is dynamically transient: beginning with Nestin+
cells, maturating through their transition to a-SMA+ cells, and
terminating with fiber residues. This niche is thus termed NSM
niche.
The Nestin+ niche cells were immunophenotypically and func-
tionally proven MSCs. Immunophenotypes of LepR+ and NG2
indicate these cells may be recruited from BM sinusoidal niches
rather than arteriolar niches (Kunisaki et al., 2013). Further inves-
tigation in the future should be performed to determine where
these cells migrate from, either the distal sinusoidal niches that
are not involved by leukemic dissemination or the proximal loci
where the sinusoidal niches is damaged by leukemic dissemina-
tion and Nestin+ MSCs fall down consequently (Figure 4N).
Our data further show that LPCs have a major function in NSM
niche formation and protection by secreting cytokines into the
BM environment in response to therapy, including chemotactic
factors and growth factors. Among them CCL3 recruited and
expanded Nestin+ cells to initiate NSM niche. TGF-b1 allowed
the niche to mature by inducing niche cell transition to a-SMA+.
GDF15 mediated the niche protection: pro-GDF15 was cleaved
by the niche cell-provided Furin to release mGDF15 that in turn
activated Smad3-mediated TGF-b signaling pathway in the
niche-resident leukemic cells, thereby providing the cells with
chemoresistance. Therefore, the interference with these cyto-
kines and enzyme or their receptors effectively overpowered
chemoresistance, thereby significantly enhancing the chemo-
therapy efficacy.
Investigation in ALL patients’ BM biopsies supports the find-
ings in themodels. NSM niche was induced by induction chemo-
therapy and its formationmight greatly contribute to the failure to(D–G) H&E staining (D and F) and leukemic burden (E andG) of BM from the ‘‘onset
represent 100 mm (D and F).
(H) Flow cytometric analysis of the leukemic engraftment in recipients of serial tr
(I) Summary of the engraftment of the three samples tested in primary, secondar
(J) Statistical summary of the LPC frequency of the three samples of residual leuke
was detected by limiting dilution transplantation in secondary recipients. All data
See also Figure S6 and Tables S1 and S2.
790 Cancer Cell 25, 778–793, June 16, 2014 ª2014 Elsevier Inc.achieve complete remission. The therapeutic strategies for such
disease should prevent the formation of the early protective
niche or interfere with its function during the early phase of
chemotherapy.
Perspective
In conclusion, a therapy-induced niche has been identified in the
BM. The niche provides the resident LPCs with antiapoptotic
properties. This kind of niche-mediated ‘‘reprogramming’’ in
LPCs is most likely achieved by epigenetic cooperation consid-
ering that most polycomb-group genes in the residual LPCs
were markedly changed either upregulated or downregulated
(data not shown). These alterations may be memorized by the
niche-resident LPCs until they evolve by generating genetically
distinct refractory subclones (Anderson et al., 2011; Ding et al.,
2012; Notta et al., 2011). Therefore, preferential microenviron-
mental niches may have an essential function in providing the
basic foundation of epigenetics and genetics in their resident
LPCs in situ in the BM. We speculate that similar principles
may be applicable to other hematopoietic malignancies or can-
cers of other tissues (Hanahan and Weinberg, 2011).
EXPERIMENTAL PROCEDURES
More detailed methods are provided in the Supplemental Experimental
Procedures.
ALL Mouse Models and Chemotherapy
Xenograft models of human ALL were established in anti-CD122 antibody-
treated NOD/SCID mice (NS122) and NOG mice. Leukemic cell transplanta-
tions were performed by intravenous or intratibial injections in mice 6–8 weeks
of age as previously described (Anderson et al., 2011; Hong et al., 2008).
Leukemic mice were treated with Ara-C (1 g/kg, intraperitoneally) or DNR
(15mg/kg, intravenously). All animal experiments were approved by the Exper-
imental Animal Ethical Committee at Shanghai Jiao Tong University School of
Medicine. Detailed methods are described in Supplemental Experimental
Procedures.
Ex Vivo Imaging
The detailed methods were described previously (Xie et al., 2009). Mouse cra-
nium was removed and embedded horizontally in a semisolid medium in a
3.5 cm dish facing the coverslip bottom. Imaging was conducted under a
confocal microscope (Figure S1A).
Immunoassays
The femurs and tibias were fixed in 4% paraformaldehyde and processed for
frozen or paraffin sections. Frozen sections were used for immunofluorescent
staining. Paraffin sections were used for immunohistochemical staining.
Isolation and Developmental Induction of NSM Niche Cells
BM mesenchymal cells were harvested and cultured in MesenCult medium
(Stem Cell Technologies) for 2 days according to the manufacturer’s instruc-
tions. Differentiations of the niche cells were induced in the medium supplied
with TGF-b1 (Peprotech), osteogenic differentiation medium (MUBMX-90021,
Cyagen), or adipogenic differentiation medium (MUBMX-90031, Cyagen).’’ mice (D and E, n = 10) and ‘‘healthy’’ mice (F andG, n = 5). *p < 0.01. Scale bars
ansplantations.
y, and tertiary recipients.
mic cells isolated from primary recipients of A0D and A4Dmice. LPC frequency
are mean ± SD, *p < 0.01, n = 3.
(legend on next page)
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Two approaches for GDF15 interference were used: retrovirus-delivered inter-
ference RNA-targeting GDF15 (iGDF15) and neutralizing anti-GDF15 antibody.
Apoptotic Analysis
Cells were cultured with 0.2 mM Ara-C for 48 hr. Cell viability was determined
by flow cytometry after double staining with Annexin-V and propididium iodide
(PI) according to the manufacturer’s instructions.
ALL Patients and BM Samples
We retrospectively studied 50 ALL patients who were diagnosed in the
Shanghai Jiaotong University-affiliated hospitals. The diagnosis and treatment
protocols were previously described (Mi et al., 2012). After giving written con-
sent, clinical data were collected and BM aspirates and biopsies were ob-
tained. The studywas approved by theMedical Ethical Committee of Shanghai
Jiaotong University-affiliated hospitals. Detailed information is described in
Supplemental Experimental Procedures.
Statistical Analysis
All data are presented as mean ± SD. Statistical comparisons between exper-
imental groups were analyzed by Student’s t test and ANOVA. Statistical sig-
nificancewas considered as p < 0.05. Kaplan-Meier survival analysis was used
to compare the survival of NALM-6-iGDF15, -NSC, and -mock mice using
GraphPad Prism 5.0 with statistical p values generated by the log rank test.
ACCESSION NUMBERS
The cDNA microarray data are deposited at Gene Expression Omnibus data-
base (http://www.ncbi.nlm.nih.gov/geo) under accession number GSE56273.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, three tables, and five movies and can be found with this article
online at http://dx.doi.org/10.1016/j.ccr.2014.04.015.
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